These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 29175378)
1. Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine. Garcia TB; Fosmire SP; Porter CC Leuk Res; 2018 Jan; 64():30-33. PubMed ID: 29175378 [TBL] [Abstract][Full Text] [Related]
2. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint. Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437 [TBL] [Abstract][Full Text] [Related]
3. AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair. Ford JB; Baturin D; Burleson TM; Van Linden AA; Kim YM; Porter CC Oncotarget; 2015 Sep; 6(29):28001-10. PubMed ID: 26334102 [TBL] [Abstract][Full Text] [Related]
4. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma. Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911 [TBL] [Abstract][Full Text] [Related]
5. PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer. Jhuraney A; Woods NT; Wright G; Rix L; Kinose F; Kroeger JL; Remily-Wood E; Cress WD; Koomen JM; Brantley SG; Gray JE; Haura EB; Rix U; Monteiro AN Mol Cancer Ther; 2016 Jul; 15(7):1669-81. PubMed ID: 27196765 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality. Van Linden AA; Baturin D; Ford JB; Fosmire SP; Gardner L; Korch C; Reigan P; Porter CC Mol Cancer Ther; 2013 Dec; 12(12):2675-84. PubMed ID: 24121103 [TBL] [Abstract][Full Text] [Related]
7. Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress. Cuneo KC; Morgan MA; Davis MA; Parcels LA; Parcels J; Karnak D; Ryan C; Liu N; Maybaum J; Lawrence TS Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):782-90. PubMed ID: 26975930 [TBL] [Abstract][Full Text] [Related]
8. Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition. Chen X; Low KH; Alexander A; Jiang Y; Karakas C; Hess KR; Carey JPW; Bui TN; Vijayaraghavan S; Evans KW; Yi M; Ellis DC; Cheung KL; Ellis IO; Fu S; Meric-Bernstam F; Hunt KK; Keyomarsi K Clin Cancer Res; 2018 Dec; 24(24):6594-6610. PubMed ID: 30181387 [TBL] [Abstract][Full Text] [Related]
9. Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination. Krajewska M; Heijink AM; Bisselink YJ; Seinstra RI; Silljé HH; de Vries EG; van Vugt MA Oncogene; 2013 Jun; 32(24):3001-8. PubMed ID: 22797065 [TBL] [Abstract][Full Text] [Related]
11. WEE1 kinase inhibitor AZD1775 induces CDK1 kinase-dependent origin firing in unperturbed G1- and S-phase cells. Moiseeva TN; Qian C; Sugitani N; Osmanbeyoglu HU; Bakkenist CJ Proc Natl Acad Sci U S A; 2019 Nov; 116(48):23891-23893. PubMed ID: 31712441 [TBL] [Abstract][Full Text] [Related]
12. Development of Potent Pyrazolopyrimidinone-Based WEE1 Inhibitors with Limited Single-Agent Cytotoxicity for Cancer Therapy. Matheson CJ; Casalvieri KA; Backos DS; Reigan P ChemMedChem; 2018 Aug; 13(16):1681-1694. PubMed ID: 29883531 [TBL] [Abstract][Full Text] [Related]
13. Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer. Sen T; Tong P; Diao L; Li L; Fan Y; Hoff J; Heymach JV; Wang J; Byers LA Clin Cancer Res; 2017 Oct; 23(20):6239-6253. PubMed ID: 28698200 [No Abstract] [Full Text] [Related]
14. A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations. Zhou L; Zhang Y; Chen S; Kmieciak M; Leng Y; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Dai Y; Grant S Leukemia; 2015 Apr; 29(4):807-18. PubMed ID: 25283841 [TBL] [Abstract][Full Text] [Related]
15. Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer. Geenen JJJ; Schellens JHM Clin Cancer Res; 2017 Aug; 23(16):4540-4544. PubMed ID: 28442503 [TBL] [Abstract][Full Text] [Related]
16. A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells. Matheson CJ; Venkataraman S; Amani V; Harris PS; Backos DS; Donson AM; Wempe MF; Foreman NK; Vibhakar R; Reigan P ACS Chem Biol; 2016 Apr; 11(4):921-30. PubMed ID: 26745241 [TBL] [Abstract][Full Text] [Related]
17. Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy. Fu S; Wang Y; Keyomarsi K; Meric-Bernstam F; Meric-Bernstein F Expert Opin Investig Drugs; 2018 Sep; 27(9):741-751. PubMed ID: 30102076 [TBL] [Abstract][Full Text] [Related]
18. Cytokinetic effects of Wee1 disruption in pancreatic cancer. Chang Q; Chandrashekhar M; Ketela T; Fedyshyn Y; Moffat J; Hedley D Cell Cycle; 2016; 15(4):593-604. PubMed ID: 26890070 [TBL] [Abstract][Full Text] [Related]
19. The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors. Parsels LA; Parsels JD; Tanska DM; Maybaum J; Lawrence TS; Morgan MA Cell Cycle; 2018; 17(9):1076-1086. PubMed ID: 29895190 [TBL] [Abstract][Full Text] [Related]
20. Pharmacological Inhibition of WEE1 Potentiates the Antitumoral Effect of the Iannuzzi CA; Indovina P; Forte IM; Di Somma S; Malfitano AM; Bruno M; Portella G; Pentimalli F; Giordano A Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33020398 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]